Abstract
Plasma levels of NZ-105 were determined after an intravenous and a single oral administration to rats and dogs.
1. When NZ-105 was administrated to rats and dogs intravenously at the doses of 1.0 and 0.3 mg/kg respectively, the plasma levels of NZ-105 declined biexponentially with the half-lives of 1.35 and 1.03 hr at the terminal elimination phase, respectively.
2. After oral administration of NZ-105 to rats at the doses of 5, 10 and 20 mg/kg, bioavailability of each dose was 19.5, 25.0, 23.9%, respectively.
3. When NZ-105 was administrated to unfasted rats orally at the dose of 10 mg/kg, the bioavailability was 10.0%. The absorption of NZ-105 was affected by food consumption.
4. After oral administration of NZ-105 to dogs at the doses of 2, 5 and 10 mg/ kg, bioavailability of each dose was 5.1, 5.6, 4.9%, respectively.
